Generics: Capitol Hill’s Super “Pay For”
This article was originally published in The Pink Sheet Daily
As the user fee legislation continues its remarkably tranquil journey with a unanimous vote in the House Energy & Commerce Committee, tweaks to the ANDA review process have helped smooth some of the rough edges.
You may also be interested in...
In letters to congressional leaders, generic drug trade group outlines six proposals that it says would save the government billions of dollars and lessen the impact of sequestration cuts.
During a markup of an FDA user-fee bill, legislators from both sides of the aisle affirmed their intent to tackle cosmetics regulation in a separate, stand-alone bill later this year. The user-fee bill omitted a section that was in place previously to implement cosmetics user fees.
Senate health committee defers action on several potentially contentious issues, with members hoping to resolve differences over FDA’s authorities on imports, shortages, foreign data and track-and-trace before the bill goes to the floor, possibly in May. Meanwhile, the House postpones its mark-up in an effort to craft a more bipartisan bill, and now will try to push the user fee package to the floor during an upcoming four-day marathon session.